Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United Kingdom
  4. London Stock Exchange
  5. HUTCHMED (China) Limited
  6. News
  7. Summary
    HCM   KYG4672N1198

HUTCHMED (CHINA) LIMITED

(HCM)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

HUTCHMED China : Goldman Sachs Downgrades Hutchison China MediTech to Neutral From Buy

09/22/2021 | 01:06pm EST


ę MT Newswires 2021
All news about HUTCHMED (CHINA) LIMITED
06:42aHUTCHMED CHINA : Highlights Fruquintinib Clinical Data to be Presented at the 2022 ASCO Ga..
PU
01/19HUTCHMED Limited Update Analysis of Ongoing International Phase I/Ib Trial of Fruquinti..
CI
01/18Hutchmed China to Present Data From Clinical Trial of Colorectal Cancer Treatment at On..
MT
01/18HUTCHMED Highlights Fruquintinib Clinical Data to be Presented at the 2022 ASCO Gastroi..
AQ
01/18TR-1 : Standard form for notification of major holdings - Form 6-K
PU
01/13Chinese Regulators Grant Breakthrough Therapy Designation to Hutchmed's Immune Thromboc..
MT
01/12HUTCHMED Secures Breakthrough Therapy Designation in China for Primary Immune Thrombocy..
MT
01/12HUTCHMED CHINA : Receives Breakşthrough Therapy Designation in China for HMPL-523 for Trea..
PU
01/12HUTCHMED Limited Receives Breakthrough Therapy Designation in China for HMPL-523 for Tr..
CI
01/10HUTCHMED CHINA : Initiates Phase I Study of BTK Inhibitor HMPL-760 in Patients with Previo..
PU
More news
Analyst Recommendations on HUTCHMED (CHINA) LIMITED
More recommendations
Financials (USD)
Sales 2021 339 M - -
Net income 2021 -262 M - -
Net cash 2021 568 M - -
P/E ratio 2021 -20,0x
Yield 2021 -
Capitalization 5 265 M 5 276 M -
EV / Sales 2021 13,9x
EV / Sales 2022 10,6x
Nbr of Employees 1 280
Free-Float 51,3%
Chart HUTCHMED (CHINA) LIMITED
Duration : Period :
HUTCHMED (China) Limited Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends HUTCHMED (CHINA) LIMITED
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 4
Last Close Price 6,15 $
Average target price 9,32 $
Spread / Average Target 51,5%
EPS Revisions
Managers and Directors
Christian Hogg Chief Executive Officer & Executive Director
Chig Fung Cheng Chief Financial Officer
Chi Keung To Executive Director
Wei Guo Su Executive Director & Chief Scientific Officer
Marek Kania Chief Medical Officer & Managing Director
Sector and Competitors
1st jan.Capi. (M$)
HUTCHMED (CHINA) LIMITED-14.72%5 257
JOHNSON & JOHNSON-2.32%439 907
ROCHE HOLDING AG-3.75%322 066
PFIZER, INC.-8.37%303 712
ABBVIE INC.1.02%241 811
ELI LILLY AND COMPANY-10.55%223 992